Taiwan-based Health2Sync, a leading digital health company specialising in chronic disease management, has raised over $20 million in a Series C funding round and earlier extension round. This investment will propel the company's growth initiatives, including expansion into new markets, development of innovative programs, and preparations for a public listing in Taiwan.
The funding round was led by Taiwania Capital, with participation from prominent investors, including Wistron, Pegatron, BE Health Ventures, ABIES Capital, and Cathay Venture. The strong support from new and existing investors underscores confidence in Health2Sync's vision and track record of what it has developed as Asia’s largest chronic disease management solution.
The company has strategically deployed the newly acquired capital to support several key initiatives- Develop and launch a series of disease management programmes: Continue developing its innovative and personalized patient engagement programs to include a digital weight-loss program targeting the need for practical weight management tools, hypertension, and other sub-health symptoms, and adding digital GLP-1 engagement to the offering as payers in the region seek to enable further drug accessibility; Expansion in key markets: accelerate its growth in strategic geographies, including Japan, South Korea and Australia, especially capitalizing on the increasing demand from the public sector for digital health solutions. Introduce Insultrate, a Software-as-a-Medical Device (SaMD) for insulin self-titration, to other geographies; Deepen the use of AI: enhance the efficiency of disease management for patients and healthcare providers and elevate user experience to the next level.
Image caption- Michael Huang, Managing Partner of Taiwania Capital (Left), and Ed Deng, Co-founder and CEO of Health2Sync (Right)
